Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors
Explore this paper's citation graph
Summary
The discovery and development of lovastatin — the first approved inhibitor of HMG-CoA reductase — and the clinical trials that have provided the evidence for the ability of drugs in this class to reduce the morbidity and mortality associated with cardiovascular disease are described.
- Type
- review
- Published
- 2003-07-01
- Cited by
- 840
- References
- 116
- OpenAlex
- https://openalex.org/W1500847299
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:3344720
Keywords
Lovastatin, HMG-CoA reductase, Reductase, Cholesterol, Coronary heart disease
References
- Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog.
- Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease.
- Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia.
- Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration
- Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
- Cataracts produced by triparanol. (MER-29).
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
- Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension.
- The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia.
- The regulation of acetoacetyl-CoA synthetase activity by modulators of cholesterol synthesis in vivo and the utilization of acetoacetate for cholesterogenesis.
- HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.
- Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth.
- Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
- Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits.
- Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering.
- Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation.
- The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks.
- Central Nervous System Effects of HMG CoA Reductase Inhibitors: Lovastatin and Pravastatin on Sleep and Cognitive Performance in Patients with Hypercholesterolemia
- Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group.
- Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials.
Cited by
- Pharmacological inhibition of endocytic pathways: is it specific enough to be useful?
- Specific activation of mitogen-activated protein kinase by transforming growth factor-beta receptors in lipid rafts is required for epithelial cell plasticity.
- Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases
- Synergistic Effect of Statins and Postmenopausal Hormone Therapy in the Prevention of Skeletal Fractures in Elderly Women
- Relationships between HMG‐CoA reductase inhibitors (statin) use and strength, balance and falls in older people
- Expression of HMGR and corresponding cholesterol content in tissues of two pig breeds.
- Target- and Mechanism-Based Therapeutics for Neurodegenerative Diseases: Strength in Numbers
- Simvastatin increases excitability in the hippocampus via a PI3 kinase-dependent mechanism.
- Regulation of Sterol Biosynthesis in the Human Fungal Pathogen Aspergillus fumigatus: Opportunities for Therapeutic Development
- Hepatoprotective Principles and Other Chemical Constituents from the Mycelium of Phellinus linteus
- Enhancement of the antioxidant and hypolipidemic activities of Puerariae radix by fermentation with Aspergillus niger
- Regulation of Lipid Homeostasis, Inflammatory Signalling and Atherosclerosis by the Peroxisome Proliferator-Activated Receptor Delta
- Statin-induced myositis: a commonly encountered or rare side effect?
- The effect of non‐marine vs. marine sources of the omega‐3 fatty acids, DHA and EPA, on serum lipoproteins
- In-silico screening of potential inhibitors of HMGCoA reductase and Lanosterol synthase, key enzymes in cholesterol biosynthesis pathway
- Novel opportunities for computational biology and sociology in drug discovery
- Antiparasitic and Anticancer Constituents of the Endophytic Fungus Aspergillus sp. strain F1544
- Avaliação da qualidade e equivalência farmacêutica de comprimidos contendo 10mg de sinvastatina
- Pharmacogenetic Determinants of Atorvastatin Metabolism and Response
- Hypocholesterolemia secondary to atrovastatin therapy.
Related papers
- 인삼의 총사포닌 , Ginsenoside-Rb1 , Ginsenoside-Rb2 와 Lovastatin 에 의한 Hep G2 세포의 HMG CoA Reductase 및 LDL 수용체 mRNA 발현 유발효과의 비교
- Effect of the cholesterol absorption inhibitor SCH48461 in combination with the HMG-CoA reductase inhibitor lovastatin in rabbits, dogs and rhesus monkeys
- Lichenoid drug eruption with HMG-CoA reductase inhibitors (fluvastatin and lovastatin).
- Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
- Cholesterol Homeostasis in Mononuclear Leukocytes from Patients with Familial Hypercholesterolemia Treated with Lovastatin
- Increase in serum and bile cholesterol and HMG-CoA reductase by lovastatin in rats.
- Cholesterol homeostasis in mononuclear leukocytes from patients with familial hypercholesterolemia treated with lovastatin.
- A review on lovastatin and its production
- Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
- Mechanisms for cholesterol homeostasis in rat jejunal mucosa: effects of cholesterol, sitosterol, and lovastatin.